1. Novartis Ag (7 from 3,923 patents)

2. Black Diamond Therapeutics, Inc. (2 from 2 patents)

1. 12466808 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors

2. 12441733 - Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors

3. 12435046 - Alkynyl quinazoline compounds

4. 11613543 - Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors

5. 11541056 - 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives

6. 11160797 - Pyridinone derivatives and their use as selective ALK-2 inhibitors

7. 11034672 - Tyrosine kinase inhibitor compositions, methods of making and methods of use

8. 10947218 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors

9. 10710980 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors